Patents Represented by Attorney, Agent or Law Firm Rekha Bansal
  • S1P1 receptor agonists and use thereof
    Patent number: 7842685
    Abstract: The present invention relates to compounds of Formula (I): that are have activity as S1P receptor modulating agents, more specifically to specifically compounds that are S1P1 receptor agonists. The invention also related to the use of such compounds to treat diseases associated with inappropriate S1P1 receptor activity such as autoimmune diseases.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: November 30, 2010
    Assignee: Amgen Inc.
    Inventors: Victor J. Cee, Michael J. Frohn, Brian Alan Lanman, Susana C. Neira, Anthony B. Reed, Kelvin K. C. Sham
  • p38 map kinase inhibitors
    Patent number: 6630485
    Abstract: The present invention relates to compounds of Formula (I) that are p-38 MAP kinase inhibitors, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: October 7, 2003
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Soan Cheng, David Michael Goldstein, Teresa Alejandra Trejo Martin, Eric Brian Sjogren
  • Compounds and compositions as cathepsin S inhibitors
    Patent number: 6492362
    Abstract: The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: December 10, 2002
    Assignee: Axys Pharmaceuticals, Inc.
    Inventors: Michael Graupe, John O. Link, John W. Patterson, Sheila Zipfel
  • p38 MAP kinase inhibitors
    Patent number: 6479507
    Abstract: The present invention relates to compounds of Formula (I) that are p-38 MAP kinase inhibitors, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: November 12, 2002
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Soan Cheng, David Michael Goldstein, Teresa Alejandra Trejo Martin, Eric Brian Sjogren
  • Selective urokinase inhibitors
    Patent number: 6465503
    Abstract: The present invention provides novel compounds of Formula I: its prodrug forms, or pharmaceutically acceptable salts thereof. The compounds of this invention are inhibitors of uPA, and have utility as cancer treating agents.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: October 15, 2002
    Assignee: Axys Pharmaceuticals, Inc.
    Inventor: Richard Laurence Mackman
  • Pyrazole derivatives-p38 map kinase inhibitors
    Patent number: 6376527
    Abstract: The present invention relates to certain pyrazole derivatives of Formula (I): that are p-38 MAP kinase inhibitors, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: April 23, 2002
    Assignee: Syntex (U.S.A.) LLC
    Inventors: David Michael Goldstein, Sharada Shenvi Labadie, David Mark Rotstein, Eric Brian Sjogren, Francisco Xavier Talamas
  • Cyclic amine derivatives-CCR-3 receptor antagonists
    Patent number: 6339087
    Abstract: This invention relates to certain cyclic amine derivatives of Formula (I) that are CCR-3 receptor antagonist, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: January 15, 2002
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Leyi Gong, Denis John Kertesz, David Bernard Smith, Francisco Xavier Talamas, Robert Stephen Wilhelm
  • Cyclic amine derivatives- CCR-3 receptor antagonists
    Patent number: 6323223
    Abstract: This invention relates to certain cyclic amine derivatives of Formula (I) that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: November 27, 2001
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Leyi Gong, Denis John Kertesz, David Bernard Smith, Francisco Xavier Talamas, Robert Stephen Wilhelm
  • P38 MAP kinase inhibitors
    Patent number: 6316464
    Abstract: The present invention relates to compounds of Formula (I) that are p-38 MAP kinase inhibitors, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
    Type: Grant
    Filed: October 16, 1998
    Date of Patent: November 13, 2001
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Soan Cheng, David Michael Goldstein, Teresa Alejandra Trejo Martin, Eric Brian Sjogren
  • 5-aroylnaphthalene derivatives as anti-inflammatory agents
    Patent number: 6150397
    Abstract: The present invention relates to certain 5-aroylnaphthalene derivatives of formula (I): ##STR1## that are inhibitors of prostaglandin G/H synthase, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
    Type: Grant
    Filed: June 21, 1999
    Date of Patent: November 21, 2000
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: David Mark Rotstein, Eric Brian Sjogren
  • Sulfamide-metalloprotease inhibitors
    Patent number: 6143744
    Abstract: This invention relates to sulfamides of formula (I) ##STR1## that are inhibitors of metalloproteases, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: November 7, 2000
    Assignees: Syntex (U.S.A.) Inc., Agouron Pharmaceuticals, Inc.
    Inventors: Chris Allen Broka, Jeffrey Allen Campbell, Arlindo Lucas Castelhano, Jian Jeffrey Chen, Robert Than Hendricks, Michael Joseph Melnick, Keith Adrian Murray Walker
  • 4-aroylpiperidine derivatives-CCR-3 receptor antagonists
    Patent number: 6140344
    Abstract: This invention relates to certain piperidine quaternary salts of Formula (I) ##STR1## that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Grant
    Filed: November 17, 1999
    Date of Patent: October 31, 2000
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Leyi Gong, Denis John Kertesz, David Berard Smith, Robert Stephen Wilhelm
  • 5-aroylpyrrol-2-ylmethylarene derivatives
    Patent number: 6136844
    Abstract: Compounds selected from the group of compounds represented by formula I: ##STR1## where: R.sub.10 is represented by the formula (A), (B), or (C): ##STR2## R.sub.20 is represented by the formula (U), (V), or (W): ##STR3## and the other substituents are as defined in the specification; and their pharmaceutically acceptable salts;are inhibitors of prostaglandin G/H synthase and are anti-inflammatory and analgesic agents.
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: October 24, 2000
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Denis J. Kertesz, Edvige Galeazzi Toscani, Deborah C. Reuter, Eric B. Sjogren
  • Sulfamide-metalloprotease inhibitors
    Patent number: 6130220
    Abstract: This invention relates to sulfamides of formula (I) ##STR1## that are inhibitors of metalloproteases, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: October 10, 2000
    Assignees: Syntex (USA) Inc., Agouron Pharmaceuticals, Inc.
    Inventors: Chris Allen Broka, Jeffrey Allen Campbell, Arlindo Lucas Castelhano, Jian Jeffrey Chen, Robert Than Hendricks, Michael Joseph Melnick, Keith Adrian Murray Walker
  • 5-aroylpyrrol-2-ylmethylarene derivatives
    Patent number: 6127402
    Abstract: Compounds selected from the group of compounds represented by formula I: where:R.sub.10 is represented by the formula (A), (B), or (C): ##STR1## R.sub.20 is represented by the formula (U), (V), or (W): ##STR2## and the other substituents are as defined in the specification; and their pharmaceutically acceptable salts;are inhibitors of prostaglandin G/H synthase and are anti-inflammatory and analgesic agents.
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: October 3, 2000
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Denis J. Kertesz, Edvige Galeazzi Toscani, Deborah C. Reuter, Eric B. Sjogren
  • Sulfamide-metalloprotease inhibitors
    Patent number: 5998412
    Abstract: This invention relates to sulfamides of formula (I) ##STR1## that are inhibitors of metalloproteases, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: December 7, 1999
    Assignees: Syntex (U.S.A.) Inc., Agouron Pharmaceuticals, Inc.
    Inventors: Chris Allen Broka, Jeffrey Allen Campbell, Arlindo Lucas Castelhano, Jian Jeffrey Chen, Robert Than Hendricks, Michael Joseph Melnick, Keith Adrian Murray Walker
  • 5-aroylnaphthalene derivatives as anti-inflammatory agents
    Patent number: 5962531
    Abstract: The present invention relates to certain 5-aroylnaphthalene derivatives of formula (I): ##STR1## that are inhibitors of prostaglandin G/H synthase, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: October 5, 1999
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: David Mark Rotstein, Eric Brian Sjogren
  • 3-aroylbenzylpyridazinone derivatives
    Patent number: 5886178
    Abstract: Compounds of formula I: ##STR1## where: R.sub.10 is a group represented by formula (A), (B), or (C): ##STR2## and the other substituents are as defined in the specification; and their pharmaceutically acceptable salts are inhibitors of prostaglandin G/H synthase and are anti-inflammatory and analgesic agents.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: March 23, 1999
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Darin A. Allen, James P. Dunn, Eric B. Sjogren, David B. Smith